763 related articles for article (PubMed ID: 21985374)
1. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease.
Tang Y; Bian Z; Zhao L; Liu Y; Liang S; Wang Q; Han X; Peng Y; Chen X; Shen L; Qiu D; Li Z; Ma X
Clin Exp Immunol; 2011 Nov; 166(2):281-90. PubMed ID: 21985374
[TBL] [Abstract][Full Text] [Related]
2. The role of hepassocin in the development of non-alcoholic fatty liver disease.
Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
[TBL] [Abstract][Full Text] [Related]
3. The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice.
Rolla S; Alchera E; Imarisio C; Bardina V; Valente G; Cappello P; Mombello C; Follenzi A; Novelli F; Carini R
Clin Sci (Lond); 2016 Feb; 130(3):193-203. PubMed ID: 26558403
[TBL] [Abstract][Full Text] [Related]
4. The imbalance of Th17/Treg cells is involved in the progression of nonalcoholic fatty liver disease in mice.
He B; Wu L; Xie W; Shao Y; Jiang J; Zhao Z; Yan M; Chen Z; Cui D
BMC Immunol; 2017 Jun; 18(1):33. PubMed ID: 28646856
[TBL] [Abstract][Full Text] [Related]
5. Sodium fluorocitrate having inhibitory effect on fatty acid uptake ameliorates high fat diet-induced non-alcoholic fatty liver disease in C57BL/6J mice.
Hong SA; Jung IR; Choi SE; Hwang Y; Lee SJ; Son Y; Heo YJ; Cui R; Han SJ; Kim HJ; Lee KW; Kang Y
Sci Rep; 2019 Nov; 9(1):17839. PubMed ID: 31780766
[TBL] [Abstract][Full Text] [Related]
6. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
[TBL] [Abstract][Full Text] [Related]
7. Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans.
Cruces-Sande M; Vila-Bedmar R; Arcones AC; González-Rodríguez Á; Rada P; Gutiérrez-de-Juan V; Vargas-Castrillón J; Iruzubieta P; Sánchez-González C; Formentini L; Crespo J; García-Monzón C; Martínez-Chantar ML; Valverde ÁM; Mayor F; Murga C
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3655-3667. PubMed ID: 30261289
[TBL] [Abstract][Full Text] [Related]
8. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
9. The Effects of RKI-1447 in a Mouse Model of Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet and in HepG2 Human Hepatocellular Carcinoma Cells Treated with Oleic Acid.
Wang J; Jiang W
Med Sci Monit; 2020 Feb; 26():e919220. PubMed ID: 32026851
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of microRNA-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the AMPK/AKT pathway.
Hur W; Lee JH; Kim SW; Kim JH; Bae SH; Kim M; Hwang D; Kim YS; Park T; Um SJ; Song BJ; Yoon SK
Int J Biochem Cell Biol; 2015 Jul; 64():265-76. PubMed ID: 25957914
[TBL] [Abstract][Full Text] [Related]
11. Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Is Marked by a Higher Frequency of Th17 Cells in the Liver and an Increased Th17/Resting Regulatory T Cell Ratio in Peripheral Blood and in the Liver.
Rau M; Schilling AK; Meertens J; Hering I; Weiss J; Jurowich C; Kudlich T; Hermanns HM; Bantel H; Beyersdorf N; Geier A
J Immunol; 2016 Jan; 196(1):97-105. PubMed ID: 26621860
[TBL] [Abstract][Full Text] [Related]
12. p53/p66Shc-mediated signaling contributes to the progression of non-alcoholic steatohepatitis in humans and mice.
Tomita K; Teratani T; Suzuki T; Oshikawa T; Yokoyama H; Shimamura K; Nishiyama K; Mataki N; Irie R; Minamino T; Okada Y; Kurihara C; Ebinuma H; Saito H; Shimizu I; Yoshida Y; Hokari R; Sugiyama K; Hatsuse K; Yamamoto J; Kanai T; Miura S; Hibi T
J Hepatol; 2012 Oct; 57(4):837-43. PubMed ID: 22641095
[TBL] [Abstract][Full Text] [Related]
13. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
Xu B; Jiang M; Chu Y; Wang W; Chen D; Li X; Zhang Z; Zhang D; Fan D; Nie Y; Shao F; Wu K; Liang J
J Hepatol; 2018 Apr; 68(4):773-782. PubMed ID: 29273476
[TBL] [Abstract][Full Text] [Related]
14. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
Lee MR; Yang HJ; Park KI; Ma JY
Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
[TBL] [Abstract][Full Text] [Related]
15. Exosomes Derived from Dendritic Cells Attenuate Liver Injury by Modulating the Balance of Treg and Th17 Cells After Ischemia Reperfusion.
Zheng L; Li Z; Ling W; Zhu D; Feng Z; Kong L
Cell Physiol Biochem; 2018; 46(2):740-756. PubMed ID: 29621784
[TBL] [Abstract][Full Text] [Related]
16. Hepatocyte X-box binding protein 1 deficiency increases liver injury in mice fed a high-fat/sugar diet.
Liu X; Henkel AS; LeCuyer BE; Schipma MJ; Anderson KA; Green RM
Am J Physiol Gastrointest Liver Physiol; 2015 Dec; 309(12):G965-74. PubMed ID: 26472223
[TBL] [Abstract][Full Text] [Related]
17. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
[TBL] [Abstract][Full Text] [Related]
18. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis.
Matsumoto M; Hada N; Sakamaki Y; Uno A; Shiga T; Tanaka C; Ito T; Katsume A; Sudoh M
Int J Exp Pathol; 2013 Apr; 94(2):93-103. PubMed ID: 23305254
[TBL] [Abstract][Full Text] [Related]
19. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models.
Jain MR; Giri SR; Bhoi B; Trivedi C; Rath A; Rathod R; Ranvir R; Kadam S; Patel H; Swain P; Roy SS; Das N; Karmakar E; Wahli W; Patel PR
Liver Int; 2018 Jun; 38(6):1084-1094. PubMed ID: 29164820
[TBL] [Abstract][Full Text] [Related]
20. Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis.
Akbari R; Behdarvand T; Afarin R; Yaghooti H; Jalali MT; Mohammadtaghvaei N
BMC Pharmacol Toxicol; 2021 Oct; 22(1):53. PubMed ID: 34593018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
